NCT05065008

Brief Summary

Clinical trials on cranberry juice and UTI prevention yielded both positive and negative results for unknown reason. Gut microbiome in women affect the absorption and metabolism of cranberry bioactives. The variation of gut microbiome is a probable mechanism for metabolic polymorphisms and disparity in UTI prevention in women.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable healthy

Timeline
3mo left

Started Oct 2021

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Oct 2021Aug 2026

First Submitted

Initial submission to the registry

September 29, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 1, 2021

Completed
17 days until next milestone

Study Start

First participant enrolled

October 18, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

September 5, 2025

Status Verified

September 1, 2025

Enrollment Period

4.8 years

First QC Date

September 29, 2021

Last Update Submit

September 4, 2025

Conditions

Keywords

CranberryUTI

Outcome Measures

Primary Outcomes (1)

  • Change in the unrinary anti-adhesion activity of UTI susceptible women

    Compare the statistical differences between the changes from baseline in the an-adhesion activity against uropathogenic E. coli in UTI-susceptible women after consuming the cranberry juice for 3 weeks versus after consuming the placebo juice for 3 weeks. Anti-adhesion activity in urine will be measured using a fluorescence-based microplate method. The anti-adhesion activities of urines will be expressed by its equivalence to myricetin level. The unit for urine anti-adhesion activities is µg myricetin/mg creatinine.

    Baseline up to 21 days of each intervention

Secondary Outcomes (2)

  • Determine the compositional differences of gut microbiome in responders and non-responders after the cranberry juice intake

    Baseline up to 21 days of each intervention

  • Identify anti-adhesion urinary biomarkers in responders versus non-responders after the cranberry juice intake

    Baseline upt to 21 days of each intervention

Study Arms (2)

Cranberry juice consumption

EXPERIMENTAL

Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) of cranberry juice daily for 3 weeks.

Other: Cranberry juice

Apple juice consumption

EXPERIMENTAL

Participants deemed as responders and non-responders will be given 20-30 oz (590-885 mL) apple juice with matching sugar and calories daily for 3 weeks.

Other: Apple juice

Interventions

The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.

Cranberry juice consumption

The participants will drink apple juice with matching sugar content and calories for 3 weeks

Apple juice consumption

Eligibility Criteria

Age21 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsWomen is a group which is susceptible to urinary tract infections (UTIs) based on previous papers. This study will determine American cranberries to prevent UTIs in susceptible women.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy women participants;
  • BMI 18.5-29.9 kg/m2;
  • At least 110 pounds in weight

You may not qualify if:

  • BMI≥ 30 kg/m2;
  • Pregnancy and breast-feeding;
  • Smoking, frequent alcohol use;
  • History of any clinically important disorder that may interfere with interpretation of the results;
  • Intake of medication that might influence the outcome of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Florida

Gainesville, Florida, 32611, United States

Location

Study Officials

  • Liwei Gu, PhD

    University of Florida

    PRINCIPAL INVESTIGATOR
  • Gary P Wang, PhD

    University of Florida

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2021

First Posted

October 1, 2021

Study Start

October 18, 2021

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

September 5, 2025

Record last verified: 2025-09

Locations